Propranolol hydrochloride (b)

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

盐酸普萘洛尔是一种广泛使用的非心脏选择性β-肾上腺素能拮抗剂。

Propranolol Hydrochloride is a widely used non-cardioselective beta-adrenergic antagonist.(In Vitro):Propranolol hydrochloride (10-7 M-10-3 M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10-5 M in HemSCs.Propranolol hydrochloride (10-9 M-10-3 M; 24 and 48 hours) significant decreases cell proliferation at 10-4 M propranolol after 24 hours and 10-9 M propranolol after 48 hours in HemSCs.Propranolol hydrochloride (50 μM-200 μM; 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces HemSC apoptosis.(In Vivo):Propranolol hydrochloride (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant.

Propranolol hydrochloride (10-7 M-10-3 M; 24 and 48 hours) increases the total ERK1/2 levels in a dose-dependent manner, and ERK1/2 activation is observed specifically at 10-5 M in HemSCs.Propranolol hydrochloride (10-9 M-10-3 M; 24 and 48 hours) significant decreases cell proliferation at 10-4 M propranolol after 24 hours and 10-9 M propranolol after 48 hours in HemSCs.Propranolol hydrochloride (50 μM-200 μM; 24 hours) increases Annexin V positivity and caspase-3 activation, rapidly induces HemSC apoptosis. Western Blot Analysis Cell Line:HemSC cells Concentration:10-7 M-10-3 M Incubation Time:24 and 48 hours Result:Increased the total ERK1/2 levels in a dose-dependent manner. Cell Viability Assay Cell Line:HemSC cells Concentration:10-9 M-10-3 M Incubation Time:24 and 48 hours Result:Suppressed HemSC Proliferation.Apoptosis Analysis Cell Line:HemSC cells Concentration:50 μM, 100 μM, or 200 μM Incubation Time:24 hours Result:Induced HemSC cell death occurred via an apoptotic pathway.

Propranolol hydrochloride (orally administration; 40 mg/kg; daily) significantly reduces the vessel diameter relative to the vehicle-treated implants, and increases the number of cells that expressed phosphorylated ERK1/2 within the IH Matrigel implant. Animal Model:A xenograft mouse model of IH (infantile hemangiomas) with HemSC cells Dosage:40 mg/kg Administration:Orally administration; 40 mg/kg; daily Result:Improved vessel development in the IH mouse model that correlated with MAPK pathway activation.

ICI 45520 | NSC 91523

Endocrinology/Hormones

Adrenergic Receptor

β-adrenergic receptor

Neurological Disease

——

318-98-9

295.81

C16H22ClNO2

>98% (HPLC)

Water: 6 mg/mL (20.28 mM); DMSO: 59 mg/mL (199.45 mM)

Cl.CC(C)NCC(O)COC1=CC=CC2=CC=CC=C12

——

(-20℃)

With Ice Pack

≥ 2 years